Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Effect of Cationic Lipid Type in Folate-PEG-Modified Cationic Liposomes on Folate Receptor-Mediated siRNA Transfection in Tumor Cells.

Hattori Y, Shimizu S, Ozaki KI, Onishi H.

Pharmaceutics. 2019 Apr 15;11(4). pii: E181. doi: 10.3390/pharmaceutics11040181.

2.

Establishment of Novel Cells Stably Secreting Various Human IL-18 Recombinant Proteins.

Kumagai A, Shimizu K, Kurata R, Cui X, Isagawa T, Harada M, Nagai J, Yoshida Y, Ozaki KI, Takeda N, Semba H, Yonezawa T.

Curr Pharm Biotechnol. 2019;20(1):47-55. doi: 10.2174/1389201020666190206203640.

PMID:
30727885
3.

Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex.

Hattori Y, Nakamura M, Takeuchi N, Tamaki K, Shimizu S, Yoshiike Y, Taguchi M, Ohno H, Ozaki KI, Onishi H.

J Drug Target. 2019 Feb;27(2):217-227. doi: 10.1080/1061186X.2018.1502775. Epub 2018 Sep 7.

PMID:
30024300
4.

Establishment of Novel Reporter Cells Stably Maintaining Transcription Factor-driven Human Secreted Alkaline Phosphatase Expression.

Kurata R, Kumagai A, Cui X, Harada M, Nagai J, Yoshida Y, Ozaki KI, Tanaka Y, Yonezawa T.

Curr Pharm Biotechnol. 2018;19(3):224-231. doi: 10.2174/1389201019666180418093334.

PMID:
29667554
5.

Therapeutic effects of protein kinase N3 small interfering RNA and doxorubicin combination therapy on liver and lung metastases.

Hattori Y, Kikuchi T, Nakamura M, Ozaki KI, Onishi H.

Oncol Lett. 2017 Nov;14(5):5157-5166. doi: 10.3892/ol.2017.6830. Epub 2017 Aug 25.

6.

Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo-like kinase 1 and heat shock transcription factor 1 small interfering RNA.

Hattori Y, Kikuchi T, Ozaki KI, Onishi H.

Exp Ther Med. 2017 Nov;14(5):4300-4306. doi: 10.3892/etm.2017.5060. Epub 2017 Aug 28.

7.

TNF-α Induces Caspase-1 Activation Independently of Simultaneously Induced NLRP3 in 3T3-L1 Cells.

Furuoka M, Ozaki K, Sadatomi D, Mamiya S, Yonezawa T, Tanimura S, Takeda K.

J Cell Physiol. 2016 Dec;231(12):2761-7. doi: 10.1002/jcp.25385. Epub 2016 Mar 30.

PMID:
26989816
8.

Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes.

Ozaki KI, Awazu M, Tamiya M, Iwasaki Y, Harada A, Kugisaki S, Tanimura S, Kohno M.

Am J Physiol Endocrinol Metab. 2016 Apr 15;310(8):E643-E651. doi: 10.1152/ajpendo.00445.2015. Epub 2016 Feb 9.

9.

Therapeutic effect for liver-metastasized tumor by sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA.

Hattori Y, Arai S, Kikuchi T, Ozaki KI, Kawano K, Yonemochi E.

J Drug Target. 2016 Apr;24(4):309-317. Epub 2015 Aug 3.

PMID:
26234899
10.

Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin.

Hattori Y, Shibuya K, Kojima K, Miatmoko A, Kawano K, Ozaki K, Yonemochi E.

Int J Oncol. 2015 Jul;47(1):211-9. doi: 10.3892/ijo.2015.2991. Epub 2015 May 7.

PMID:
25955490
11.

Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.

Sakamoto T, Ozaki K, Fujio K, Kajikawa SH, Uesato S, Watanabe K, Tanimura S, Koji T, Kohno M.

Biochem Biophys Res Commun. 2013 Apr 19;433(4):456-62. doi: 10.1016/j.bbrc.2013.03.009. Epub 2013 Mar 15.

PMID:
23501104
12.

Atypical protein phosphatases: emerging players in cellular signaling.

Sadatomi D, Tanimura S, Ozaki K, Takeda K.

Int J Mol Sci. 2013 Feb 26;14(3):4596-612. doi: 10.3390/ijms14034596.

13.

Targeting the extracellular signal-regulated kinase pathway in cancer therapy.

Kohno M, Tanimura S, Ozaki K.

Biol Pharm Bull. 2011;34(12):1781-4. Review.

14.

Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.

Watanabe K, Tanimura S, Uchiyama A, Sakamoto T, Kawabata T, Ozaki K, Kohno M.

Clin Cancer Res. 2010 Feb 15;16(4):1170-8. doi: 10.1158/1078-0432.CCR-09-2482. Epub 2010 Feb 9.

15.

Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.

Ozaki K, Kosugi M, Baba N, Fujio K, Sakamoto T, Kimura S, Tanimura S, Kohno M.

Biochem Biophys Res Commun. 2010 Jan 22;391(4):1610-5. doi: 10.1016/j.bbrc.2009.12.086. Epub 2009 Dec 22.

PMID:
20026060
16.

Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubule-destabilizing agents in tumor cells.

Tanimura S, Uchiyama A, Watanabe K, Yasunaga M, Inada Y, Kawabata T, Iwashita K, Noda S, Ozaki K, Kohno M.

Biochem Biophys Res Commun. 2009 Jan 16;378(3):650-5. doi: 10.1016/j.bbrc.2008.11.109. Epub 2008 Dec 4.

PMID:
19059207
17.

Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.

Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M.

Cancer Sci. 2008 Feb;99(2):376-84. doi: 10.1111/j.1349-7006.2007.00669.x. Epub 2008 Jan 15.

18.

Anticancer drugs up-regulate HspBP1 and thereby antagonize the prosurvival function of Hsp70 in tumor cells.

Tanimura S, Hirano AI, Hashizume J, Yasunaga M, Kawabata T, Ozaki K, Kohno M.

J Biol Chem. 2007 Dec 7;282(49):35430-9. Epub 2007 Sep 12.

19.

Supplemental Content

Loading ...
Support Center